Table 2. Baseline Clinical Features in the Studies Included in the Meta-analysis.
| Source | Age, y | % | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Male | DM | STEMI | NSTEMI | Unstable Angina | DAPT | PCI | Prior Stroke | ||
| APPRAISE | 61 | 75 | 22 | 62.9 | 29.5 | 7.6 | 75.5 | 65 | 4 |
| APPRAISE 2 | 67 | 69 | 48 | 39.6 | 41.6 | 18.1 | 81 | 44 | 10 |
| APPRAISE J | 64.6 | 87 | 40 | 75.5 | 15.2 | 9.3 | 97.4 | 99 | 4 |
| ATLAS ACS TIMI 46 | 57.4 | 77 | 19 | 52.2 | 29.9 | 18.0 | 78.2 | 64 | NA |
| ATLAS ACS 2 TIMI 51 | 61.7 | 75 | 32 | 50.4 | 25.6 | 24.0 | 93 | 57 | NA |
| REDEEM | 61.8 | 60 | 31 | 60 | 40 | - | 99.2 | 55 | NA |
Abbreviations: APPRAISE, Apixaban for Prevention of Acute Ischemic Events; ATLAS ACS TIMI 46, Rivaroxaban versus Placebo in Patients With Acute Coronary Syndromes; CKD, chronic kidney disease; DAPT, dual antiplatelet therapy; DM, diabetes; NA, not applicable; NSTEMI, non–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; REDEEM, Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome; STEMI, ST-segment elevation myocardial infarction.